Orchid Pharma has announced its financial performance for the quarter and year ended March 31, 2026. The company reported a standalone annual revenue of ₹81,132.73 lakh and a net profit of ₹4,520.79 lakh. During the year, the company focused on key acquisitions, including Allecra Therapeutics and Orchid Pharma Europe GmbH, to consolidate its global antibiotic product ownership and expand its market presence. The company also appointed M/s. T R Chadha & Co., LLP as Internal Auditor.
Annual Financial Performance Highlights
For the financial year ended March 31, 2026, Orchid Pharma recorded a consolidated total income of ₹84,650.06 lakh, with a consolidated net profit of ₹2,054.70 lakh. On a standalone basis, the company achieved a total income of ₹86,656.92 lakh and a net profit of ₹4,520.79 lakh. These figures reflect the company’s operational activities throughout the fiscal year, including strategic adjustments for exceptional items related to labor law provisions.
Strategic Acquisitions and Growth
The company made significant strides in expanding its global footprint by acquiring 100% of the assets of Allecra Therapeutics GmbH (Germany) and Allecra Therapeutics SAS (France). This move grants Orchid Pharma total global ownership of Enmetazobactam, a novel antibiotic molecule, allowing for full control and repatriation of the brand to India. Additionally, the company acquired 100% share capital of Weilchensee 1272. V V GmbH, now operating as Orchid Pharma Europe GmbH, further strengthening its international operational capabilities.
Corporate Governance and Operational Updates
The company is currently undergoing an amalgamation process with its holding company, Dhanuka Laboratories Limited, following approval from the Board of Directors and the completion of necessary shareholder and creditor formalities. The matter is currently awaiting the final order from the National Company Law Tribunal (NCLT). Furthermore, the company has appointed M/s. T R Chadha & Co., LLP to serve as the Internal Auditor for the 2026-27 financial year to ensure robust internal oversight and process compliance.
Source: BSE
